MR spectroscopy: Its potential role for drug development for the treatment of psychiatric diseases

NMR in Biomedicine

Volumn 19, Issue 6, 2006, Pages 690-701

  Mason, Graeme F ^a   Krystal, John H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Amino acids; Glutamate; Glutamine; Mood disorders; MRS; NAA; Neurotransmitters; Schizophrenia

Indexed keywords

GLUTAMATE; GLUTAMINE; MOOD DISORDERS; NEUROTRANSMITTERS; PSYCHIATRIC DISEASES; SCHIZOPHRENIA;

AMINO ACIDS; BIOCHEMISTRY; BIOLOGICAL RADIATION EFFECTS; BIOMARKERS; CONTROLLED DRUG DELIVERY; MAGNETIC RESONANCE SPECTROSCOPY; NEUROLOGY; PSYCHOPHYSIOLOGY;

DRUG PRODUCTS;

4 AMINOBUTYRIC ACID; ALCOHOL; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CARBON 13; CHOLINE; DIAMORPHINE; FLUORINE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; LITHIUM; LITHIUM 7; LITHIUM SALT; METHAMPHETAMINE; MOOD STABILIZER; N ACETYLASPARTIC ACID; NEUROLEPTIC AGENT; PHOSPHORUS 31; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VALPROIC ACID;

ANXIETY DISORDER; BEHAVIOR THERAPY; BIOCHEMISTRY; BIPOLAR DISORDER; COGNITIVE DEFECT; COGNITIVE THERAPY; DETOXIFICATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG INDUSTRY; DRUG SYNTHESIS; ELECTROCONVULSIVE THERAPY; HUMAN; IONIZING RADIATION; MENTAL DISEASE; MOOD DISORDER; NEUROCHEMISTRY; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOPHYSIOLOGY; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA;

ASPARTIC ACID; BIOLOGICAL MARKERS; CHOLINE; DRUG EVALUATION; HUMANS; INOSITOL; MAGNETIC RESONANCE SPECTROSCOPY; MENTAL DISORDERS; NEUROTRANSMITTER AGENTS;

EID: 33749495245     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.1080     Document Type: Review

References (157)

1. Duatti A. In vivo imaging of oligonucleotides with nuclear tomography. Curr. Drug Targ. 2004; 5: 753-760.
2. Talbot PS, Laruelle M. The role of in vivo molecular imaging with PET and SPECT in the elucidation of psychiatric drug action and new drug development. 2002, Eur. Neuropsychopharm. 12: 503-511.
3. Swanson JM, Volkow ND. Pharmacokinetic and pharmacodynamic properties of stimulants: implications for the design of new treatments for ADHD. 2002, Behav. Brain Res. 130: 73-78.
4. Miller JC, Pien HH, Sahani D, Sorensen AG, Thrall JH. Imaging angiogenesis: applications and potential for drug development. 2005, J. Natl Cancer Inst. 97: 172-187.
5. Rudin M, Sauter A. In vivo NMR in pharmaceutical research. 1992, Magn. Reson. Imag. 10: 723-731.
6. Lindon JC, Holmes E, Nicholson JK. Metabonomics: systems biology in pharmaceutical research and development. 2004, Curr. Opin. Mol. Ther. 6: 265-272.
7. Martinez D, Broft A, Laruelle M. Imaging neurochemical endophenotypes: promises and pitfalls. 2001, Pharmacogenomics 2: 223-237.
8. Moffett JR, Namboodiri MA, Cangro CB, Neale JH. Immunohistochemical localization of N-acetylaspartate in rat brain. 1991, Neuroreport 2: 131-134.
9. Urenjak J, Williams SR, Gadian DG, Noble M. Specific expression of N-acetylaspartate in neurons, oligodendrocytes in vitro. 1992, J. Neurochem. 59: 55-61.
10. Moreno A, Ross BD, Blüml S. Direct determination of the N-acetyl-L-aspartate synthesis rate in the human brain by (13)C MRS and [1-(I3)C] glucose infusion. 2001, J. Neurochem. 77: 347-350.
11. Patel TB, Clark JB. Synthesis of N-acetyl-L-aspartate by rat brain mitochondria and its involvement in mitochondrial/cytosolic carbon transport. 1979, Biochem. J. 184: 539-546.
12. +. 1994, J. Neurochem. 62: 2349-2355.
13. Sager TN, Thomsen C, Valsborg JS, Laursen H, Hansen AJ. Astroglia contain a specific transport mechanism for N-acetyl-L-aspartate. 1999, J. Neurochem. 73: 807-811.
14. Baslow MH, Resnik TR. Canavan disease. Analysis of the nature of the metabolic lesions responsible for development of the observed clinical symptoms. 1997, J. Mol. Neurosci. 9: 109-125.
15. Bhakoo KK, Craig TJ, Styles P. Developmental and regional distribution of aspartoacylase in rat brain tissue. 2001, J. Neurochem. 79: 211-220.
16. D'Adamo A, Yatsu F. Acetate metabolism in the nervous system. N-acetyl-L-aspartic acid and the biosynthesis of brain lipids. 1966, J. Neurochem. 13: 961-965.
17. Burri R, Steffen C, Herschkowitz N. N-acetyl-L-aspartate is a major source of acetyl groups for lipid synthesis during rat brain development. 1991, Dev. Neurosci. 13: 403-411.
18. O'Neill J, Eberling JL, Schuff N, Jagust W, Reed B, Soto G, Ezekiel F, Klein G, Weiner MW. Method to correlate 1H MRSI and 18FDG-PET. 2000, Magn. Reson. Med. 43: 244-250.
19. 1H magnetic resonance spectroscopy study at 4.0 Tesla. 2004, Psychiat. Res. 131: 107-114.
20. Gimenez M, Junque C, Perez M, Vendrell P, Baeza I, Salamero M, Mercader JM, Bernardo M. Basal ganglia N-acetylaspartate correlates with the performance in the procedural task 'Tower of Hanoi' of neuroleptic-naive schizophrenic patients. 2003, Neurosci. Lett. 347: 97-100.
21. Blasi G, Bertolino A, Brudaglio F, Sciota D, Altamura M, Antonucci N, Scarabino T, Weinberger DR, Nardini M. Hippocampal neurochemical pathology in patients at first episode of affective psychosis: a proton magnetic resonance spectroscopic imaging study. 2004, Psychiat. Res. 131: 95-105.
22. Ende G, Braus DF, Walter S, Weber-Fahr W, Soher B, Maudsley AA, Henn FA. Effects of age, medication, and illness duration on the N-acetyl aspartate signal of the anterior cingulate region in schizophrenia. 2000, Schizophren. Res. 41: 389-395.
23. Callicott JH, Bertolino A, Egan MF, Mattay VS, Langheim FJP, Weinberger DR. Selective relationship between prefrontal N-acetylaspartate measures and negative symptoms in schizophrenia. 2000, Am. J. Psychiat. 157: 1646-1651.
24. Bartha R, al-Semaan YM, Williamson PC, Drost DJ, Malla AK, Carr TJ, Densmore M, Canaran G, Neufeld RW. A short echo proton magnetic resonance spectroscopy study of the left mesial-temporal lobe in first-onset schizophrenic patients. 1999, Biol. Psychiat. 45: 1403-1411.
25. Lindquist DM, Hawk RM, Karson CN, Komoroski RA. Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. 2000, Magn. Reson. Med. 43: 355-358.
26. Bustillo J, Wolff C, Myers-y-Gutierrez A, Dettmer TS, Cooper TB, Allan A, Lauriello J, Valenzuela CF. Treatment of rats with antipsychotic drugs: lack of an effect on brain N-acetyl aspartate levels. 2004, Schizophren. Res. 66: 31-39.
27. Bustillo JR, Lauriello J, Rowland LM, Jung RE, Petropoulos H, Hart BL, Blanchard J, Keith SJ, Brooks WM. Effects of chronic haloperidol and clozapine treatments on frontal and caudate neurochemistry in schizophrenia. 2001, Psychiat. Res. 107: 135-149.
28. Bustillo JR, Lauriello J, Rowland LM, Thomson LM, Petropoulos H, Hammond R, Hart B, Brooks WM. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. 2002, Schizophren. Res. 58: 313-321.
29. Braus DF, Ende G, Weber-Fahr W, Demirakca T, Tost H, Henn FA. Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. 2002, Eur Neuropsychopharm. 12: 145-152.
30. Braus DF, Ende G, Weber-Fahr W, Demirakca T, Henn FA. Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. 2001, Pharmacopsychiatry 34: 251-253.
31. Pae CU, Choe BY, Joo RH, Lim HK, Kim TS, Yoo SS, Choi BG, Kim JJ, Lee SJ, Lee C, Paik IH, Lee CU. Neuronal dysfunction of the frontal lobe in schizophrenia. 2004, Neuropsychobiology 50: 211-215.
32. Narr K, Thompson P, Sharma T, Moussai J, Zoumalan C, Rayman J, Toga A. Three-dimensional mapping of gyral shape and cortical surface asymmetries in schizophrenia: gender effects. 2001, Am J. Psychiat. 158: 244-255.
33. Sullivan EV, Lim KO, Mathalon D, Marsh L, Beal DM, Harris D, Hoff AL, Faustman WO, Pfefferbaum A. A profile of cortical gray matter volume deficits characteristic of schizophrenia. 1998, Cereb. Cortex 8: 117-124.
34. Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. 2004, Neuromol. Med 5: 11-25.
35. Michael N, Erfurth A, Ohrmann P, Arolt V, Heindel W, Pfleiderer B. Neurotrophic effects of electroconvulsive therapy: a proton magnetic resonance study of the left amygdalar region in patients with treatment-resistant depression. 2003, Neuropsychopharmacology 28: 720-725.
36. Sheline YI, Gado MH, Kraemer HC. Untreated depression and hippocampal volume loss. 2003, Am J. Psychiat. 160: 1516-1518.
37. Czeh B, Michaelis T, Watanabe T, Frahm J, de Biurrun G, van Kampen M, Bartolomucci A, Fuchs E. Stress-induced changes in cerebral metabolites, hippocampal volume, and cell proliferation are prevented by antidepressant treatment with tianeptine. 2001, Proc. Natl Acad. Sci. USA. 98: 12796-12801.
38. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, Staib LH, Charney DS, Bremner JD. Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. 2004, Biol. Psychiat. 56: 101-112.
39. Moore GJ, Bebchuk JM, Hasanat K, Chen G, Sarji-Bozorgzad N, Wilds IB, Faulk MW, Koch S, Glitz DA, Jolkovsky L, Manji HK. Lithium increases N-acetyl-aspartate in the human brain: in vivo evidence in support of bcl-2's neurotrophic effects?2000, Biol. Psychiat. 48: 1-8.
40. Silverstone PH, Wu RH, O'Donnell T, Ulrich M, Asghar SJ, Hanstock CC. Chronic treatment with lithium, but not sodium valproate, increases cortical N-acetyl-aspartate concentrations in euthymic bipolar patients. 2003, Int. Clin. Psychopharm. 18: 73-79.
41. Obergriesser T, Ende G, Braus DF, Henn FA. Long-term follow-up of magnetic resonance-detectable choline signal changes in the hippocampus of patients treated with electroconvulsive therapy. 2003, J. Clin. Psychiat. 64: 775-780.
42. Bendszus M, Weijers HG, Wiesbeck G, Warmuth-Metz M, Bartsch AJ, Engels S, Boning J, Solymosi L. Sequential MR imaging and proton MR spectroscopy in patients who underwent recent detoxification for chronic alcoholism: correlation with clinical and neuropsychological data. 2001, Am J. Neuroradiol. 22: 1926-1932.
43. Jagannathan NR, Desai NG, Raghunathan P. Brain metabolite changes in alcoholism: an in vivo proton magnetic resonance spectroscopy (MRS) study. 1996, Magn. Reson. Imag. 14: 553-557.
44. Parks MH, Dawant BM, Riddle WR, Hartmann SL, Dietrich MS, Nickel MK, Price RR, Martin PR. Longitudinal brain metabolic characterization of chronic alcoholics with proton magnetic resonance spectroscopy. 2002, Alcohol Clin. Exp. Res. 26: 1368-1380.
45. 1H magnetic resonance spectroscopy investigation of alcohol-associated frontal lobe injury. 2001, Alcohol Clin. Exp. Res. 25: 924-934.
46. Martin PR, Gibbs SJ, Nimmerrichter AA, Riddle WR, Welch LW, Willcott MR. Brain proton magnetic resonance spectroscopy studies in recently abstinent alcoholics. 1995, Alcohol Clin. Exp. Res. 19: 1078-1082.
47. Nordahl TE, Salo R, Possin K, Gibson DR, Flynn N, Leamon M, Galloway GP, Pfefferbaum A, Spielman DM, Adalsteinsson E, Sullivan EV. Low N-acetyl-aspartate and high choline in the anterior cingulum of recently abstinent methamphetamine-dependent subjects: a preliminary proton MRS study. 2002, Psychiat. Res. 116: 43-52.
48. Haselhorst R, Dursteler-MacFarland KM, Scheffler K, Ladewig D, Muller-Spahn F, Stohler R, Seelig J, Seifritz; E. Frontocortical N-acetylaspartate reduction associated with long-term i.v. heroin use. 2002, Neurology 58: 305-307.
49. Reneman L, Majoie CB, Flick H, den Heeten GJ. Reduced N-acetylaspartate levels in the frontal cortex of 3,4-methylenedioxy-methamphetamine (Ecstasy) users: preliminary results. 2002, Am. J. Neuroradiol. 23: 231-237.
50. Reneman L, Majoie CB, Schmand B, van den Brink W, den Heeten GJ. Prefrontal N-acetylaspartate is strongly associated with memory performance in (abstinent) ecstasy users: preliminary report. 2001, Biol. Psychiat. 50: 550-554.
51. Sanacora G, Rothman DL, Mason G, Krystal JH. Clinical studies implementing glutamate neurotransmission in mood disorders. 2003, Ann NY Acad. Sci. 1003: 292-308.
52. Coyle JT. The GABA-glutamate connection in schizophrenia: which is the proximate cause?2004, Biochem. Pharmac. 68: 1507-1514.
53. Javitt DC. Glutamate as a therapeutic target in psychiatric disorders. 2004, Mol. Psychiat. 9: 984-997.
54. Ketter TA, Wang PW. The emerging differential roles of GABA-ergic and antiglutamatergic agents in bipolar disorders. 2003, J. Clin. Psychiat. 3: 15-20.
55. Pralong E, Magistretti P, Stoop R. Cellular perspectives on the glutamate-monoamine interactions in limbic lobe structures and their relevance for some psychiatric disorders. 2002, Prog. Neurobiol. 67: 173-202.
56. Kassem MNE, Bartha R. Quantitative proton short-echo-time LASER spectroscopy of normal human white matter and hippocampus at 4 Tesla incorporating macromolecule subtraction. 2003, Magn. Reson. Med. 49: 918-927.
57. 1H NMR spectrum of rat brain. 1993, Magn. Reson. Med. 30: 38-44.
58. Hwang JH, Graham GD, Behar KL, Alger JR, Prichard JW, Rothman DL. Short echo time proton magnetic rsonance spectroscopic imaging of macromolecule and metabolite signal intensities in the human brain. 1996, Magn. Reson. Med. 35: 633-639.
59. 1H NMR spectra of human brain. 1994, Magn. Reson. Med. 32: 294-302.
60. Hofmann L, Slotboom J, Boesch C, Kreis R. Characterization of the macromolecule baseline in localized (1)H-MR spectra of human brain. 2001, Magn. Reson. Med. 46: 855-863.
61. 1H NMR measurements of γ-aminobutyric acid in human brain in vivo. 1993, Proc. Natl Acad. Sci. USA. 90: 5662-5666.
62. Mader I, Karitzky J, Klose U, Seeger U, Sperfeld A, Naegele T, Schick F, Ludolph A, Grodd W. Proton MRS in Kennedy disease: absolute metabolite and macromolecular concentrations. 2002, J. Magn. Reson. Imag. 16: 160-167.
63. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. 2003, Psychopharmacology 169: 215-233.
64. Winterer G, Weinberger DR. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. 2004, Trends Neurosci. 27: 683-690.
65. Laruelle M, Kegeles LS, Abi-Dargham A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. 2003, Ann NY Acad Sci. 1003: 138-158.
66. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, Canaran MacFabe G, Rylett RJ, Neufeld RWJ. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. 1997, Arch. Gen. Psychiat. 54: 959-965.
67. Choe BY, Kim KT, Suh TS, Lee C, Paik IH, Bahk YW, Shinn KS, Lenkinski RE. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. 1994, Acad. Radiol. 1: 211-216.
68. Kegeles LS, Shungu DC, Anjilvel S, Chan S, Ellis SP, Xanthopoulos E, Malaspina D, Gorman JM, Mann JJ, Laruelle M, Kaufmann CA. Hippocampal pathology in schizophrenia: magnetic resonance imaging and spectroscopy studies. 2000, Psychiat. Res. 98: 163-175.
69. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. 2004, Am J. Psychiat. 161: 1116-1118.
70. Théberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, Neufeld RW, Rogers J, Pavlosky W, Schaefer B, Densmore M, Al-Semaan Y, Williamson PC. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. 2003, Am J. Psychiat. 159: 1944-1946.
71. Goff DC, Hennen J, Lyoo IK, Tsai G, Wald LL, Evins AE, Yurgelun-Todd DA, Renshaw PF. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. 2002, Biol. Psychiat. 51: 493-497.
72. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, Thompson RT. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. 1996, Schizophren. Bull. 22: 597-609.
73. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH. Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. 1996, Invest. Radiol. 31: 345-352.
74. Volk DW, Lewis DA. Impaired prefrontal inhibition in schizophrenia: relevance for cognitive dysfunction. 2002, Phys. Behav. 77: 501-505.
75. Bhagwagar Z, Wylezinska M, Ashworth F, Sule A, Jezzard P, Matthews P, Cowen PJ. Proc. American College of Neuropsychopharmacology, San Juan, PR, 2004; 27.
76. Hasler G, Neumeister A, van der Veen J, T. T, Bain EE, Shen J, Drevets WC, Charney DS. Proc. American College of Neuropsychopharmacology, San Juan, PR, 2004. Program no. 60.
77. Lakoff A. The mousetrap: managing the placebo effect in antidepressant trials. 2002, Mol. Intervent. 2: 72-76.
78. Quitkin FM, Rabkin JG. Methodological problems in studies of depressive disorder: utility of the discontinuation design. 1981, J. Clin. Psychopharm. 1: 283-288.
79. Sanacora G, Fenton L, Fasula MR, D.L., Krystal JH, Mason GF. Cortical GABA concentrations in depressed patients receiving cognitive behavioral therapy. 2004, Biol. Psychiat. 59: 284-286.
80. Bhagwagar Z, Wylezinska M, Taylor M, Jezzard P, Matthews PM, Cowen PJ. Increased brain GABA concentrations following acute administration of a selective serotonin reuptake inhibitor. 2004, Am J. Psychiat. 161: 368-370.
81. Sanacora G, Mason GF, Rothman DL, Krystal JH. Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. 2002, Am J. Psychiat. 159: 663-665.
82. Friedman SD, Dager SR, Parow A, Hirashima F, Demopulos C, Stoll AL, Lyoo IK, Dunner DL, Renshaw PF. Lithium and valproic acid treatment effects on brain chemistry in bipolar disorder. 2004, Biol. Psychiat. 56: 340-348.
83. Krystal JH, Sanacora G, Blumberg H, Anand A, Charney DS, Marek G, Epperson CN, Goddard A, Mason GF. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. 2002, Mol. Psychiat. 7: S71-80.
84. Grachev ID, Apkarian AV. Anxiety in healthy humans is associated with orbital frontal chemistry. 2000, Mol. Psychiat. 5: 482-488.
85. Goddard AW, Mason GF, Almai A, Rothman DL, Behar KL, Petroff OA, Charney DS, Krystal JH. Reductions in occipital cortex GABA levels in panic disorder detected with 1H-magnetic resonance spectroscopy. 2001, Arch. Gen. Psychiat. 58: 556-561.
86. 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. 1999, Am. J. Psychiat. 156: 952-954.
87. Mason GF, Petrakis IL, de Graaf RA, Gueorguieva R, Guidone E, Coric V, Epperson CN, Rothman DL, Krystal JH. Cortical gamma-aminobutyric acid levels and the recovery from ethanol dependence: preliminary evidence of modification by cigarette smoking. 2006, Biol. Physchiatry 59: 85-93.
88. Adinoff B, Kramer GL, Petty F. Levels of gamma-aminobutyric acid in cerebrospinal fluid and plasma during alcohol withdrawal. 1995, Psychiat. Res. 59: 137-144.
89. Myrick H, Anton R. Recent advances in the pharmacotherapy of alcoholism. 2004, Curr. Psychiat. Rep. 6: 332-338.
90. Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmelhoch JM, Thase ME. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. 2005, Arch. Gen. Psychiat. 62: 37-45.
91. Kenna GA, McGeary JE, Swift RM. Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, part 1. 2004, Am. J. Health Syst. Pharm. 61: 2272-2279.
92. 123I]iomazenil SPECT and GABA MRS. 1999, Epilepsia 40: 1433-1438.
93. Isaacks RE, Bender AS, Kim CY, Prieto NM, Norenberg MD. Osmotic regulation of myo-inositol uptake in primary astrocyte cultures. 1994, Neurochem. Res. 19: 331-338.
94. Manji HK, Bersudsky Y, Chen G, Belmaker RH, Potter WZ. Modulation of protein kinase C isozymes and substrates by lithium: the role of myo-inositol. 1996, Neuropsychopharmacology 15: 370-381.
95. Chang K, Adleman N, Dienes K, Barnea-Goraly N, Reiss A, Ketter T. Decreased N-acetylaspartate in children with familial bipolar disorder. 2003, Biol. Psychiat. 53: 1059-1065.
96. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK. Temporal dissociation between lithium-induced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. 1999, Am. J. Psychiat. 156: 1902-1908.
97. Sartorius A, Neumann-Haefelin C, Vollmayr B, Hoehn M, Henn FA. Choline rise in the rat hippocampus induced by electroconvulsive shock treatment. 2003, Biol. Psychiat. 53: 620-623.
98. Frederick Bd, Satlin A, Wald LL, Hennen J, Bodick N, Renshaw PF. Brain proton magnetic resonance spectroscopy in Alzheimer disease: changes after treatment with xanomeline. 2002, Am. J. Gen. Psychiat. 10: 81-88.
99. 1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. 1997, Am. J. Psychiat. 154: 1459-1461.
100. Stoll AL, Sachs GS, Cohen BM, Lafer B, Christensen JD, Renshaw PF. Choline in the treatment of rapid-cycling bipolar disorder: clinical and neurochemical findings in lithium-treated patients. 1996, Biol. Psychiat. 40: 382-388.
101. Lyoo IK, Demopulos CM, Hirashima F, Ahn KH, Renshaw PF. Oral choline decreases brain purine levels in lithium-treated subjects with rapid-cycling bipolar disorder: a double-blind trial using proton and lithium magnetic resonance spectroscopy. 2003, Bipolar Disord. 5: 300-306.
102. Stanley JA. In vivo magnetic resonance spectroscopy and its application to neuropsychiatric disorders. 2002, Can. J. Psychiat. 47: 315-326.
103. 31 P nuclear magnetic resonance spectroscopy findings in bipolar illness: a meta-analysis. 2001, Psychiat. Res. 106: 181-191.
104. 31P magnetic resonance spectroscopy in the frontal lobe of major depressed patients. 1998, Eur Arch. Psychiat. Clin. Neurosci. 248: 289-295.
105. Christensen JD, Renshaw PF, Stoll AL, Lafer B, Fava M. Proc. Society for Magnetic Resonance Medicine, San Francisco, CA, 1994; 608.
106. Moore CM, Christensen JD, Lafer B, Fava M, Renshaw PF. Lower levels of nucleoside triphosphate in the basal ganglia of depressed subjects: a phosphorous-31 magnetic resonance spectroscopy study. 1997, Am. J. Psychiat. 154: 116-118.
107. 31Phosphorus magnetic resonance spectroscopy of the frontal and parietal lobes in chronic schizophrenia. 1994, Biol. Psychiat. 36: 503-510.
108. Pettegrew JW, Keshavan MS, Panchalingam K, Strychor S, Kaplan DB, Tretta. MG, Allen M. Alterations in brain high-energy phosphate and membrane phospholipid metabolism in first-episode, drug-naive schizophrenics. 1991, Arch. Gen. Psychiat. 48: 563-568.
109. 31P-MR spectroscopy study. 1994, Schizophren. Res. 13: 209-215.
110. 31P chemical shift imaging study of medicated schizophrenic patients and healthy controls. 1999, Biol. Psychiat. 45: 687-693.
111. 31P-MRS chemical shift imaging study at 4 Tesla. 2004, Br. J. Psychiat. 184: 409-415.
112. Williamson P, Drost D, Stanley J, Carr T, Morrison S, Merskey H. Localized phosphorus 31 magnetic resonance spectroscopy in chronic schizophrenic patients and normal controls. 1991, Arch. Gen. Psychiat. 48: 578 [Erratum appears in Arch. Gen. Psychiat. 1991; 48(8): 759.]
113. 31P magnetic resonance chemical shift imaging. 1992, Acta Psychiat. Scand. 86: 455-462.
114. 31Phosphorus magnetic resonance spectroscopy of the dorsolateral prefrontal region in schizophrenics - a study including 50 patients and 36 controls. 1998, Biol. Psychiat. 44: 399-404.
115. Jensen JE, Al-Semaan YM, Williamson PC, Neufeld RW, Menon RS, Schaeffer B, Densmore M, Drost DJ. Region-specific changes in phospholipid metabolism in chronic, medicated schizophrenia: (31)P-MRS study at 4.0 Tesla. 2002, Br. J. Psychiat. 180: 39-44.
116. 31P NMR spectroscopy shows an increase in glycerophosphorylcholine concentration without alterations in mitochondrial function in the prefrontal cortex of medicated schizophrenic patients at rest. 2004, Eur. J. Neurosci. 20: 749-756.
117. Meyerhoff DJ, MacKay S, Sappey-Marinier D, Deicken R, Calabrese G, Dillon WP, Weiner MW, Fein G. Effects of chronic alcohol abuse and HIV infection on brain phosphorus metabolites. 1995, Alcohol Clin. Exp. Res. 19: 685-692.
118. 3lP MRS study. 2001, Alcohol Clin. Exp. Res. 25: 89-97.
119. 31P magnetic resonance spectroscopy study. 2001, Alcohol Clin. Exp. Res. 25: 1213-1220.
120. Komoroski RA, Lindquist DM. Biomedical Magnetic Resonance: Proceedings of International Workshop, Jagannathan NR. Jaypee Brothers Medical Publishers: New Delhi, 2005.
121. Strauss WL, Unis AS, Cowan C, Dawson G, Dager SR. Fluorine magnetic resonance spectroscopy measurement of brain fluvoxamine and fluoxetine in pediatric patients treated for pervasive developmental disorders. 2002, Am. J. Psychiat. 159: 755-760.
122. Henry ME, Moore CM, Kaufman MJ, Michelson D, Schmidt ME, Stoddard E, Vuckevic AJ, Berreira PJ, Cohen BM, Renshaw PF. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. 2000, Am. J. Psychiat. 157: 1506-1508.
123. Strauss WL, Layton ME, Dager SR. Characterization of human brain pharmacokinetics using a two-compartment model. 1999, Biol. Psychiat. 45: 1384-1388.
124. Komoroski RA, Newton JE, Cardwell D, Sprigg J, Pearce J, Karson CN. In vivo 19F spin relaxation and localized spectroscopy of fluoxetine in human brain. 1994, Magn. Reson. Med. 31: 204-211.
125. Renshaw PF, Guimaraes AR, Fava M, Rosenbaum JF, Pearlman JD, Flood JG, Puopolo PR, Clancy K, Gonzalez RG. Accumulation of fluoxetine and norfluoxetine in human brain during therapeutic administration. 1992, Am. J. Psychiat. 149: 1592-1594.
126. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Kornoroski RA. Human brain fluoxetine concentrations. 1993, J. Neuropsychiat. Clin. Neurosci. 5: 322-329.
127. 19F nuclear magnetic resonance of a monofluorinated neuroleptic in the rat. 1993, NMR Biomed. 6: 27-31.
128. l9F nuclear magnetic resonance spectroscopy of trifluorinated neuroleptics in the rat. 1990, NMR Biomed. 3: 120-123.
129. 19F-nuclear magnetic resonance spectroscopy study. 1992, Psychiat. Res. 45: 95-104.
130. Bolo NR, Hode Y, Macher JP. Long-term sequestration of fluorinated compounds in tissues after fluvoxamine or fluoxetine treatment: a fluorine magnetic resonance spectroscopy study in vivo. 2004, Magma 16: 268-276.
131. Bolo NR, Hode Y, Nedelec JF, Laine E, Wagner G, Macher JP. Brain pharmacokinetics and tissue distribution in vivo of fluvoxamine and fluoxetine by fluorine magnetic resonance spectroscopy. 2000, Neuropsychopharmacology 23: 428-438.
132. Gonzalez RG, Guimaraes AR, Sachs GS, Rosenbaum JF, Garwood M, Renshaw PF. Measurement of human brain lithium in vivo by MR spectroscopy. 1027, AJNR Am. J. Neuroradiol. 1993; 14: 1027-1037. [Erratum appears in AJNR Am. J. Neuroradiol. 1993; 14: 1450.]
133. Moore CM, Demopulos CM, Henry ME, Steingard RJ, Zamvil L, Katic A, Breeze JL, Moore JC, Cohen BM, Renshaw PF. Brain-to-serum lithium ratio and age: an in vivo magnetic resonance spectroscopy study. 2002, Am. J. Psychiat. 159: 1240-1242.
134. Jensen HV, Plenge P, Stensgaard A, Mellerup ET, Thomsen C, Aggernaes H, Henriksen O. Twelve-hour brain lithium concentration in lithium maintenance treatment of manic-depressive disorder: daily versus alternate-day dosing schedule. 1996, Psychopharmacology 124: 275-278.
135. Plenge P, Stensgaard A, Jensen HV, Thomsen C, Mellerup ET, Henriksen O. 24-hour lithium concentration in human brain studied by Li-7 magnetic resonance spectroscopy. 1994, Biol. Psychiat. 36: 511-516.
136. Ramaprasad S. Lithium spectroscopic imaging of rat brain at therapeutic doses. 2004, Magn. Reson. Imag. 22: 727-734.
137. Mason GF, Rothman DL, Behar KL, Shulman RG. NMR determination of TCA cycle rate and a-ketoglutarate/glutamate exchange rate in rat brain. 1992, J. Cereb. Blood Flow Metab. 12: 434-447.
138. Mason GF, Gruetter R, Rothman DL, Behar KL, Shulman RG, Novotny EJ. Simultaneous determination of the rates of the TCA cycle, glucose utilization, a-ketoglutarate/glutamate exchange, and glutamine synthesis in human brain by NMR. 1995, J. Cereb. Blood Flow Metab. 15: 12-25.
139. Mason GF, Martin DL, Martin SB, Manor D, Sibson NR, Patel A, Rothman DL, Behar KL. Decrease in GABA synthesis rate in rat cortex following GABA-transaminase inhibition correlates with the decrease in GAD(67) protein. 2001, Brain Res. 914: 81-91.
140. 13C NMR measurements of cerebral glutamine synthesis as evidence for glutamate-glutamine cycling. 1997, Proc. Natl Acad. Sci. USA 94: 2699-2704.
141. Sibson NR, Dhankhar A, Mason GF, Rothman DL, Behar KL, Shulman RG. Stoichiometric coupling of brain glucose metabolism and glutamate cycling. 1998, Proc. Natl Acad. Sci. USA 95: 316-321.
142. Gruetter R, Seaquist ER, Ugurbil K. A mathematical model of compartmentalized neurotransmitter metabolism in the human brain. 2001, Am J. Physiol. 281: E100-112.
143. 13C nuclear magnetic resonance spectroscopy: elucidation of the dominant pathway for neurotransmitter glutamate repletion and measurement of astrocytic oxidative metabolism. 2002, J. Neurosci. 22: 1523-1531.
144. 13C NMR spectroscopic study of rats after administering [2-13C]] glucose with or without ammonium acetate. 1999, Brain Res. 841: 11-19.
145. 13C-magnetic resonance spectroscopy. 1998, Dev. Neurosci. 20: 427-433.
146. Blüml S, Moreno-Torres A, Shic F, Nguy CH, Ross BD. Tricarboxylic acid cycle of glia in the in vivo human brain. 2002, NMR Biomed. 15: 1-5.
147. 13C isotopomer analysis of glucose and alanine metabolism reveals cytosolic pyruvate compartmentation as part of energy metabolism in astrocytes. 2001, Glia 34: 200-212.
148. I3C] magnetic resonance spectroscopy at 4.1 T. 1999, J. Cereb Blood Flow Metab. 19: 1179-1188.
149. Mason GF, Sanacora G, R. H, M. A, Rothman DL, Krystal JH. Proc. American College of Nettropsychopharmacology, Waikaloa Hilton, HI, 2001; 202.
150. Sanacora G, Mason GF, Rothman DL, Behar KL, Hyder F, Petroff OA, Berman RM, Charney DS, Krystal JH. Reduced cortical gamma-aminobutyric acid levels in depressed patients determined by proton magnetic resonance
151. Kumar A, Newberg A, Alavi A, Berlin J, Smith R, Reivich M. Regional cerebral glucose metabolism in late-life depression and Alzheimer disease: a preliminary positron emission tomography study. 1993, Proc. Natl Acad. Sci. USA 90: 7019-7023.
152. Dunn RT, Kimbrell TA, Ketter TA, Frye MA, Willis MW, Luckenbaugh DA, Post RM. Principal components of the Beck Depression Inventory and regional cerebral metabolism in unipolar and bipolar depression. 2002, Biol. Psychiat. 51: 387-399.
153. Kimbrell TA, Ketter TA, George MS, Little JT, Benson BE, Willis MW, Herscovitch P, Post RM. Regional cerebral glucose utilization in patients with a range of severities of unipolar depression. 2002, Biol. Psychiat. 51: 237-252.
154. 13C MRS at 1.5 T. 1999, J. Magn. Reson. 136: 219-225.
155. Blüml S, Moreno-Torres A, Ross BD. [1-13C]glucose MRS in chronic hepatic encephalopathy in man. 2001, Magn. Reson. Med. 45: 981-993.
156. 13C-NMR spectroscopy. 2002, Magn. Reson. Med. 48: 1063-1067.
157. Mason GF, Falk Petersen K, de Graaf RA, Kanamatsu T, Otsuki T, Rothman DL. A comparison of (I3)C NMR measurements of the rates of glutamine synthesis and the tricarboxylic acid cycle during oral and intravenous administration of [1-(13)C]glucose. 2003, Brain Res. Protocol. 10: 181-190.